Solid Biosciences Inc. (SLDB)
Largest Insider Buys in Sector
SLDB Stock Price History Chart
SLDB Stock Performance
About Solid Biosciences Inc.
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one …
Insider Activity of Solid Biosciences Inc.
Over the last 12 months, insiders at Solid Biosciences Inc. have bought $23.87M and sold $195,207 worth of Solid Biosciences Inc. stock.
On average, over the past 5 years, insiders at Solid Biosciences Inc. have bought $39.62M and sold $269,182 worth of stock each year.
Highest buying activity among insiders over the last 12 months: PERCEPTIVE ADVISORS LLC () — $339.5M. RA CAPITAL MANAGEMENT, L.P. () — $150M. Kahn Clare (director) — $8,442.
The last purchase of 1,100 shares for transaction amount of $8,442 was made by Kahn Clare (director) on 2024‑06‑07.
List of Insider Buy and Sell Transactions, Solid Biosciences Inc.
| 2024-12-03 | Sale | President and CEO | 11,114 0.0299% | $5.60 | $62,236 | -4.25% | ||
| 2024-12-03 | Sale | Chief Operating Officer | 5,072 0.0136% | $5.60 | $28,396 | -4.25% | ||
| 2024-12-03 | Sale | Chief Regulatory Officer | 4,610 0.0124% | $5.60 | $25,822 | -4.25% | ||
| 2024-12-03 | Sale | Chief Technology Officer | 2,777 0.0075% | $5.60 | $15,551 | -4.25% | ||
| 2024-10-21 | Sale | Chief Medical Officer | 2,923 0.0085% | $6.50 | $19,000 | -6.19% | ||
| 2024-06-07 | director | 1,100 0.0027% | $7.67 | $8,442 | -14.27% | |||
| 2024-05-02 | Sale | director | 462 0.0012% | $10.33 | $4,772 | -26.49% | ||
| 2024-01-29 | Sale | director | 139 0.0007% | $7.99 | $1,111 | +1.96% | ||
| 2024-01-11 | 3.41M 12.2033% | $5.53 | $18.86M | +2.29% | ||||
| 2024-01-11 | 904,160 3.235% | $5.53 | $5M | +2.29% | ||||
| 2024-01-09 | Sale | CFO & Treasurer | 3,935 0.0194% | $8.20 | $32,267 | -2.07% | ||
| 2024-01-03 | Sale | director | 1,142 0.0052% | $5.30 | $6,052 | +39.37% | ||
| 2023-12-04 | Sale | President and CEO | 11,757 0.0459% | $2.77 | $32,516 | +125.71% | ||
| 2023-12-04 | Sale | Chief Operating Officer | 5,367 0.0211% | $2.78 | $14,920 | +125.71% | ||
| 2023-12-04 | Sale | CSO | 4,890 0.0191% | $2.77 | $13,525 | +125.71% | ||
| 2023-12-04 | Sale | Chief Regulatory Officer | 4,879 0.0191% | $2.78 | $13,562 | +125.71% | ||
| 2023-12-04 | Sale | Chief Technology Officer | 2,968 0.0116% | $2.77 | $8,232 | +125.71% | ||
| 2023-05-02 | Sale | director | 487 0.0023% | $4.85 | $2,364 | +1.91% | ||
| 2023-01-27 | Sale | Chief Scientific Officer | 441 0.0022% | $7.49 | $3,303 | -36.78% | ||
| 2023-01-27 | Sale | director | 1,523 0.0076% | $7.49 | $11,407 | -36.78% |
Insider Historical Profitability
| PERCEPTIVE ADVISORS LLC | 6833539 17.1033% | $4.16 | 4 | 0 | <0.0001% | |
| RA CAPITAL MANAGEMENT, L.P. | 4192216 10.4924% | $4.16 | 2 | 0 | <0.0001% | |
| Kahn Clare | director | 1100 0.0028% | $4.16 | 1 | 0 | |
| Shah Rajeev M. | director | 2689444 6.7312% | $4.16 | 1 | 0 | |
| Koppel Adam | director | 1989444 4.9793% | $4.16 | 1 | 0 |
Institutional Investor Ownership
| Perceptive Advisors | $92M | 18 | 6.91M | +97.56% | +$45.43M | 0.06 | |
| RA Capital Management, L.P. | $57.68M | 11.28 | 4.33M | +26.39% | +$12.04M | 0.06 | |
| Bain Capital Life Sciences Investors Llc | $53.74M | 10.51 | 4.03M | +28.88% | +$12.04M | 4.32 | |
| Adage Capital Partners Gp L L C | $33.82M | 6.62 | 2.54M | New | +$33.82M | 0.06 | |
| Artal Group S A | $33.3M | 6.51 | 2.5M | +174.96% | +$21.19M | 0.15 |